Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SA14-14-2
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms26010195 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Byung-Hak Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Animal Dairy and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT 84322, USA. Hauptthemen laut MEDLINE: Zika Virus, Zika Virus Infection, Japanese Encephalitis Vaccines, Viral Vaccines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 206 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Utah Science Technology and Research, Utah Agricultural Experiment Station, the American Board of Obstetrics and Gynecology, the American College of Obstetricians and Gynecologists, the American Society for Reproductive Medicine, and t….
Abstract (Originalsprache)
Zika virus (ZIKV) is a medically important mosquito-borne orthoflavivirus, but no vaccines are currently available to prevent ZIKV-associated disease. In this study, we compared three recombinant chimeric viruses developed as candidate vaccine prototypes (rJEV/ZIKVMR-766, rJEV/ZIKVP6-740, and rJEV/ZIKVPRVABC-59), in which the two neutralizing antibody-inducing prM and E genes from each of three genetically distinct ZIKV strains were used to replace the corresponding genes of the clinically proven live-attenuated Japanese encephalitis virus vaccine SA14-14-2 (rJEV). In WHO-certified Vero cells (a cell line suitable for vaccine production), rJEV/ZIKVP6-740 exhibited the slowest viral growth, formed the smallest plaques, and displayed a unique protein expression profile with the highest ratio of prM to cleaved M when compared to the other two chimeric viruses, rJEV/ZIKVMR-766 and rJEV/ZIKVPRVABC-59, as well as their vector, rJEV. In IFNAR−/− mice, an animal model of ZIKV infection, subcutaneous inoculation of rJEV/ZIKVP6-740 caused a low-level localized infection limited to the spleen, with no clinical signs of infection, weight loss, or mortality; in contrast, the other two chimeric viruses and their vector caused high-level systemic infections involving multiple organs, consistently leading to clear clinical signs of infection, rapid weight loss, and 100% mortality. Subsequently, subcutaneous immunization with rJEV/ZIKVP6-740 proved highly effective, offering complete protection against a lethal intramuscular ZIKV challenge 28 days after a single-dose immunization. This protection was specific to ZIKV prM/E and likely mediated by neutralizing antibodies targeting ZIKV prM/E. Therefore, our data indicate that the chimeric virus rJEV/ZIKVP6-740 is a highly promising vaccine prototype for developing a safe and effective vaccine for inducing neutralizing antibody-mediated protective immunity against ZIKV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Animal Dairy and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT 84322, USA.
- Institute for Antiviral Research, Utah State University, Logan, UT 84322, USA.
- Department of Veterinary Clinical and Life Sciences, College of Veterinary Medicine, Center for Integrated BioSystems, Utah State University, Logan, UT 84322, USA.
- Utah Agricultural Experiment Station, Utah State University, Logan, UT 84322, USA.
ORCID-Profile: Jeffrey B Mason, Irina A Polejaeva, Kenneth L White, Xin Dai, Young-Min Lee
Förderung
- Utah Science Technology and Research
- Utah Agricultural Experiment Station
- the American Board of Obstetrics and Gynecology, the American College of Obstetricians and Gynecologists, the American Society for Reproductive Medicine, and t…
- Utah Science Technology and Research initiative
- American Board of Obstetrics and Gynecology, the American College of Obstetricians and Gynecologists, the American Society for Reproductive Medicine, and the S…
Zitieren
APA
Song, B. H., Frank, J. C., Yun, S. I., Julander, J. G., Mason, J. B., Polejaeva, I. A., Davies, C. J., White, K. L., Dai, X., & Lee, Y. M. (2024). Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SA14-14-2. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26010195
Vancouver
Song BH, Frank JC, Yun SI, Julander JG, Mason JB, Polejaeva IA, et al. Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SA14-14-2. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms26010195
BibTeX
@article{Song2024,
author = {Song, Byung-Hak and Frank, Jordan C and Yun, Sang-Im and Julander, Justin G and Mason, Jeffrey B and Polejaeva, Irina A and Davies, Christopher J and White, Kenneth L and Dai, Xin and Lee, Young-Min},
title = {Comparison of Three Chimeric Zika Vaccine Prototypes Developed on the Genetic Background of the Clinically Proven Live-Attenuated Japanese Encephalitis Vaccine SA14-14-2},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms26010195}
}
EUVIMED